Tucatinib
Also known as Tukysa (us)
Tucatinib is used with trastuzumab (Herceptin) and capecitabine (Xeloda) to treat a certain type of hormone receptor–positive breast cancer that has spread to other parts of the body and cannot be treated with surgery in adults who have already been treated with at least one other chemotherapy medication.
SMILES: CC1=C(C=CC(=C1)NC2=NC=NC3=C2C=C(C=C3)NC4=NC(CO4)(C)C)OC5=CC6=NC=NN6C=C5
Based on 30 units per month. US $196.59 vs India $8.03 per unit.
The savings here are large enough that a trip may still come out ahead. Adjust the numbers to your own situation — every value is an editable estimate.
- Medicine savings over 6 months
- $33,942
- Estimated travel cost
- − $2,300
- Net savings after travel
- $31,642
Even after travel, you could come out ahead by about $31,642.
Assumptions: medicine savings = (US − India monthly price) × months. Travel cost = flights + hotel × nights + buffer. Excludes consultation fees, visas, and other costs. For information only — not medical, legal, or travel advice.
Tucatinib is filled about 6.5K times a year under Medicare Part D. At the prices above, that works out to roughly:
Rough estimate. Based on Medicare Part D prescription volume (not the entire US market) scaled by the representative monthly price — actual totals depend on dose, duration and coverage.